Search

Your search keyword '"An, Jingjing"' showing total 4 results
4 results on '"An, Jingjing"'

1. Osteopontin as a biomarker for osteosarcoma therapy and prognosis

Author

Xingwen Han, Jingjing He, Wenji Wang, Xun Li, and Lei Jiang

Subjects
0301 basic medicine, Cancer Research, osteopontin, Review, Malignancy, Metastasis, 03 medical and health sciences, 0302 clinical medicine, stomatognathic system, osteosarcoma, medicine, metastasis, Osteopontin, therapy, biology, business.industry, Melanoma, Cancer, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Osteosarcoma, Biomarker (medicine), biomarker, prognosis, business, Ovarian cancer
Abstract

Osteosarcoma (OS) is the most common bone malignancy, and is particularly prevalent in children and adolescents. OS is an aggressive tumor with a tendency to metastasize and invade to para-carcinoma tissues. The primary treatment for this tumor is a combination of surgery and chemotherapy. However, the prognosis remains poor due to chemoresistance and early metastasis. Osteopontin (OPN), a multifunctional secreted protein, has emerged as an important potential biomarker for diagnosing and treating cancer. The overexpression of OPN has been found in numerous malignant tumors, including breast, lung, gastric and ovarian cancer, as well as melanoma. Recent studies have suggested that OPN may provide an important function in the diagnosis and treatment of OS. The present review summarizes current knowledge and progress in understanding the potential role of OPN as a biomarker in OS.

Published
2018

2. Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer

Author

Xiaochen Wang, Lifang Yao, Jinlan Shan, Jian Wang, Shizhen Zhang, Xingchang Ren, Jingjing Wu, Zujian Hu, Lirong Chen, and Rui Lei

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, high mobility group A1, body mass index, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, breast cancer, Internal medicine, medicine, Risk of mortality, Oncogene, Proportional hazards model, business.industry, Cancer, Articles, medicine.disease, Molecular medicine, 030104 developmental biology, 030220 oncology & carcinogenesis, Biomarker (medicine), biomarker, prognosis, business, Body mass index
Abstract

The high mobility group A1 (HMGA1) protein is associated with poor prognosis in patients with a wide range of cancers. However, the affect of HMGA1 on the risk of mortality from breast cancer (BC) has not been fully characterized. In the present retrospective multiple center study, the HMGA1 expression level was determined by performing immunohistochemistry on surgical tissue samples of 273 BC specimens from the Second Affiliated Hospital of Zhejiang University (Zhejiang, China) and 310 BCs from the National Engineering Center for Biochip (Shanghai, China). Kaplan-Meier analysis and Cox proportional hazard model were employed to analyze the survivability. HMGA1 expression was significantly associated with tumor histological degree and body mass index (BMI). However, HMGA1 expression showed no prognostic value in patients with BC. Combined evaluation of HMGA1 expression and high BMI (≥24 kg/m2) predicted worse overall survival of BC. Therefore, HMGA1 and BMI were considered to serve synergistic roles in the development and progression of BC, and combined evaluation of HMGA1 expression and high BMI may be an effective marker in predicting poor prognosis of BC patients.

Published
2016

3. Osteopontin as a biomarker for osteosarcoma therapy and prognosis.

Author

Han, Xingwen, Wang, Wenji, He, Jingjing, Jiang, Lei, and Li, Xun

Subjects
OSTEOPONTIN, CANCER, MELANOMA, COMBINATION drug therapy, OVARIAN cancer, OSTEOSARCOMA
Abstract

Osteosarcoma (OS) is the most common bone malignancy, and is particularly prevalent in children and adolescents. OS is an aggressive tumor with a tendency to metastasize and invade to para-carcinoma tissues. The primary treatment for this tumor is a combination of surgery and chemotherapy. However, the prognosis remains poor due to chemoresistance and early metastasis. Osteopontin (OPN), a multifunctional secreted protein, has emerged as an important potential biomarker for diagnosing and treating cancer. The overexpression of OPN has been found in numerous malignant tumors, including breast, lung, gastric and ovarian cancer, as well as melanoma. Recent studies have suggested that OPN may provide an important function in the diagnosis and treatment of OS. The present review summarizes current knowledge and progress in understanding the potential role of OPN as a biomarker in OS. [ABSTRACT FROM AUTHOR]

Published
2019

4. Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer.

Author

SHIZHEN ZHANG, RUI LEI, JINGJING WU, JINLAN SHAN, ZUJIAN HU, LIRONG CHEN, XINGCHANG REN, LIFANG YAO, JIAN WANG, and XIAOCHEN WANG

Subjects
HIGH mobility group proteins, BODY mass index, BREAST cancer prognosis, CANCER-related mortality, PROTEIN expression
Abstract

The high mobility group A1 (HMGA1) protein is associated with poor prognosis in patients with a wide range of cancers. However, the affect of HMGA1 on the risk of mortality from breast cancer (BC) has not been fully characterized. In the present retrospective multiple center study, the HMGA1 expression level was determined by performing immunohistochemistry on surgical tissue samples of 273 BC specimens from the Second Affiliated Hospital of Zhejiang University (Zhejiang, China) and 310 BCs from the National Engineering Center for Biochip (Shanghai, China). Kaplan-Meier analysis and Cox proportional hazard model were employed to analyze the survivability. HMGA1 expression was significantly associated with tumor histological degree and body mass index (BMI). However, HMGA1 expression showed no prognostic value in patients with BC. Combined evaluation of HMGA1 expression and high BMI (≥24 kg/m2) predicted worse overall survival of BC. Therefore, HMGA1 and BMI were considered to serve synergistic roles in the development and progression of BC, and combined evaluation of HMGA1 expression and high BMI may be an effective marker in predicting poor prognosis of BC patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results